Schroder Investment Management Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Schroder Investment Management Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.28M	Sell	172,086 -7,011	-4%	-$174K	﹤0.01%	778
2026 Q1	$3.46M	Buy	179,097 +3,462	+2%	+$78K	﹤0.01%	836
2025 Q4	$4M	Buy	175,635 +25,064	+17%	+$824K	﹤0.01%	792
2025 Q3	$4.57M	Sell	150,571 -185,602	-55%	-$5.57M	﹤0.01%	785
2025 Q2	$12.2M	Buy	336,173 +71,888	+27%	+$2.59M	0.01%	603
2025 Q1	$10M	Sell	264,285 -111,876	-30%	-$4.65M	0.01%	639
2024 Q4	$15.9M	Buy	376,161 +193,296	+106%	+$9.59M	0.02%	565
2024 Q3	$9.95M	Sell	182,865 -174,573	-49%	-$8.89M	0.01%	662
2024 Q2	$14.7M	Buy	357,438 +102,360	+40%	+$4.37M	0.02%	548
2024 Q1	$11.9M	Buy	255,078 +5,026	+2%	+$237K	0.01%	617
2023 Q4	$12M	Buy	+250,052	New	+$9.69M	0.02%	601

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Schroder Investment Management Group's RARE Position: Q2 2026 in Review

Schroder Investment Management Group reduced its Ultragenyx Pharmaceutical (RARE) stake by 3.9% in Q2 2026, selling an estimated $174K and leaving 172,086 shares worth $5.28M. The position accounts for ﹤0.01% of the portfolio, ranked #778.

Schroder Investment Management Group first reported a position in RARE in Q4 2023 and has held it in 11 quarters since. The position peaked at $15.9M in Q4 2024. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Schroder Investment Management Group held 172,086 shares of Ultragenyx Pharmaceutical worth $5.28M as of Q2 2026.
Schroder Investment Management Group sold 7,011 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $174K.
Ultragenyx Pharmaceutical made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #778 holding.
Schroder Investment Management Group first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and has held it in 11 quarters since.
Schroder Investment Management Group's Ultragenyx Pharmaceutical position peaked at $15.9M in Q4 2024.
310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.